Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America (Q44464294)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

author name string

Sergio Poli-Bigelli

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Jose Rodrigues-Pereira

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Alexandra D Carides

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Guoguang Julie Ma

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Krista Eldridge

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Anita Hipple

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Judith K Evans

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Kevin J Horgan

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Francesca Lawson

9

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Aprepitant Protocol 054 Study Group

10

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

language of work or name

0 references

publication date

1 June 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

97

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

3090-3098

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

The changeable nature of patients' fears regarding chemotherapy: implications for palliative care

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug treatment of chemotherapy-induced delayed emesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential of substance P antagonists as antiemetics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposal for classifying the acute emetogenicity of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life consequences of chemotherapy-induced emesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiemetic study methodology: recommendations for future studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Serotonin mechanisms in chemotherapy-induced emesis in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11433

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11433

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44464294&oldid=2024896932"